Teva PharmaceuticalsTEVA
About: Teva Pharmaceutical Industries, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
Employees: 35,686
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
109% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 45
81% more call options, than puts
Call options by funds: $727M | Put options by funds: $402M
31% more capital invested
Capital invested by funds: $11.2B [Q3] → $14.7B (+$3.43B) [Q4]
29% more funds holding in top 10
Funds holding in top 10: 28 [Q3] → 36 (+8) [Q4]
7% more funds holding
Funds holding: 533 [Q3] → 568 (+35) [Q4]
2.7% more ownership
Funds ownership: 55.99% [Q3] → 58.69% (+2.7%) [Q4]
2% more repeat investments, than reductions
Existing positions increased: 191 | Existing positions reduced: 187
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
JP Morgan Chris Schott 41% 1-year accuracy 7 / 17 met price target | 36%upside $23 | Overweight Upgraded | 12 May 2025 |
B of A Securities Jason Gerberry 35% 1-year accuracy 7 / 20 met price target | 30%upside $22 | Buy Maintained | 8 May 2025 |
Financial journalist opinion
Based on 20 articles about TEVA published over the past 30 days
